Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2023 Oct 13;18(10):e0291875. doi: 10.1371/journal.pone.0291875

Structural congenital anomalies in resource limited setting, 2023: A systematic review and meta-analysis

Yohannes Fikadu Geda 1,*, Yirgalem Yosef Lamiso 1,, Tamirat Melis Berhe 1,, Seid Jemal Mohammed 1,, Samuel Ejeta Chibsa 2,, Tadesse Sahle Adeba 1,, Kenzudin Assfa Mossa 1,, Seblework Abeje 1,, Molalegn Mesele Gesese 3,
Editor: Abay Woday Tadesse4
PMCID: PMC10575536  PMID: 37831686

Abstract

Background

A number of studies have looked at neonatal structural birth defects. However, there is no study with a comprehensive review of structural anomalies. Therefor we aimed to verify the best available articles to pool possible risk factors of structural congenital anomalies in resource limited settings.

Setting

Genuine search of the research articles was done via PubMed, Scopes, Cochrane library, the Web of Science; free Google database search engines, Google Scholar, and Science Direct databases. Published and unpublished articles were searched and screened for inclusion in the final analysis and Studies without sound methodologies, and review and meta-analysis were not included in this analysis.

Participants

This review analyzed data from 95,755 women who have birthed from as reported by primary studies. Ten articles were included in this systematic review and meta-analysis. Articles which have no full information important for the analysis and case reports were excluded from the study.

Results

The overall pooled effect estimate of structural congenital anomalies was 5.50 [4.88–6.12]. In this systematic review and meta-analysis maternal illness effect estimate (EI) with odds ratio (OR) = 4.93 (95%CI 1.02–8.85), unidentified drug use OR = 2.83 (95%CI 1.19–4.46), birth weight OR = 4.20 (95%CI 2.12–6.28), chewing chat OR = 3.73 (95%CI 1.20–6.30), chemical exposure OR = 4.27 (95%CI 1.19–8.44) and taking folic acid tablet during pregnancy OR = 6.01 (95%CI 2.87–14.89) were statistically significant in this meta-regression.

Conclusions

The overall pooled effect estimate of structural congenital anomalies in a resource limited setting was high compared to better resource countries. On the Meta-regression maternal illness, unidentified drug use, birth weight, chewing chat, chemical exposure and never using folic acid were found to be statistically significant variables Preconception care and adequate intake of folic acid before and during early pregnancy should be advised.

Background

Congenital abnormalities (CA), often known as birth defects, are prenatal structural or functional changes that can be identified during pregnancy, labor, and delivery, or even years after birth [1, 2]. We may classify it as primary or minor abnormalities based on the magnitude of the structural and functional conditions and the need for medical support or treatment [1, 3, 4].

Congenital malformation can damage a variety of organs, depending on the stage of development at the time when the harm occurred [5, 6]. The most common congenital anomalies, according to some research, are those of the central nervous system [5, 6]. Heart and neural tube deformities and Down syndrome are the most frequent congenital abnormalities [1, 7].

About 50% of birth defects do not have a definite cause; however, some genetic problems, environmental agents and infectious agents are known risk factors [8, 9]. The contribution of parental chromosomal abnormalities is about 2–4%; the contributions of anatomical abnormality, endocrine factors, and antiphospholipid antibody syndrome are about 10%–15%, 20%–27%, and 17–20%, respectively [10]. Many of the known causes of congenital abnormalities can be prevented through vaccination and appropriate prenatal care during pregnancy [8, 11, 12].

Overall, it is estimated that around 7.9 million (6%) children were born with congenital abnormalities [1, 2]. According to a World Health Organization (WHO) report, congenital abnormalities account for between 17% and 42% of infant mortality [13], from 2000 to 2016, approximately 295,000 children died in the first 28 days following birth [14].

Congenital abnormalities were the fifth leading cause of death in children under five years of age, accounting for over 10% of all under-five deaths [15]. Birth defects are estimated at 94 per cent [16] and 96% of deaths due to congenital anomalies occur in low and middle-income countries (LMIC) [15].

In sub-Saharan Africa, birth defects are thought to be responsible for 10% of deaths of children under the age of five [15]. Between 2.8% and 15.9% of people in Nigeria are said to have congenital anomalies [5], and it was 0.9–17.3% in Ethiopia [1719].

Some of the congenital anomalies that have been reported in Ethiopia include anencephaly, hydrocephalus, spina bifida, meningomyelocele, umbilical hernia, upper and lower limb, cardiovascular system, digestive system, abdominal wall, unspecified congenital malformations, Down syndrome, genitourinary system, head, face, and neck defects, cleft lip and palate, clubfoot, and hernias [1721].

Maternal age, the percentage of women who live in cities, educational attainment, nutritional status, usage of herbal and over-the-counter drugs, supplementation with folic acid, alcohol intake, and employment status are socio-demographic factors are associated with congenital abnormalities [2224]. The likelihood of a successful pregnancy is typically close to 80% if the causes of birth defects are found and treated [25]. If not, congenital anomalies can have lifelong effects and can be treated with both surgical and non-surgical methods [20]. Despite this, congenital anomalies have received little attention in low resource settings, leaving a significant knowledge and understanding gap regarding their prevalence and risk factors [15, 23, 24].

Despite the fact that several primary articles have been written about potential risk factors for structural congenital defects in settings with limited resources, there is no study that might be used as benchmark with pooled value in such settings. Therefor this systematic review and meta-analysis was carried out to examine the pooled potential risk factors of structural congenital abnormalities in resource-limited settings. The result and conclusion of this study will provide scientific information for program planners, other researchers, and policy developers to improve service delivery. Besides, it will be useful for health professionals in using evidence based practices to provide the services.

Methods

2.1 Study design and setting

The authors assessed the PROSPERO database (https://www.crd.york.ac.uk/PROSPERO/) for all published or ongoing research available related to the title to skip any further duplication. Accordingly the result brought that there were no ongoing or published articles in the area of this title. Therefor this review and meta-analysis was registered in the PROSPERO database with an identification number of CRD42022384838 on 28/12/2022. This review and meta-analysis was conducted to verify the pooled possible risk factors of structural congenital anomalies in resource limited settings. Scientific consistency was formulated by using PRISMA checklist [26].

2.2 Information source

A systematic and genuine search of the research articles was done via the following listed databases. PubMed, Scopes, Cochrane library, the Web of Science, free Google database search engines, Google Scholar, and Science Direct search engines were included in the review. We have used the keywords and MeSH terms (S1 File).

The search was performed using the following key search terms: “AND” and “OR” boolean operators individually and in combination with each other. Moreover, the reference lists of all the included studies were also searched to identify any other studies that may have been missed by the search strategy. The search for all research was done from October 10th to December 5th, 2022 without limiting the publication dates of the literatures.

2.3 Eligibility criteria

2.3.1 Inclusion criteria

Published articles in national and international journals, and unpublished articles from institutional repositories conducted in resource limited settings with a result of possible risk factors of structural congenital anomalies were included in this study. Published and unpublished articles were searched and screened for inclusion in the final analysis. This study included in available observational study designs (cross-sectional studies and case-control studies). All research that was published, master’s thesis found in institutional repositories, and PhD dissertation accessed from the repositories till the final date of data analysis and submission of this manuscript to this journal were included in accordance with these criteria.

During the beginning of our search 42 studies were found of which 13 were skipped due to duplication and the rest 29 studies were identified for eligibility. From 29 studies 10 were excluded from highlight review on their abstracts and 19 studies assessed for full text of this 9 studies excluded because of not relevant to the current review and the remaining 10 studies were included in the final meta-analysis of this study (Fig 1).

Fig 1. PRISMA flow diagrams of included studies in the Systematic Review and Meta-analysis on possible risk factors of congenital anomalies in resource limited setting, 2022.

Fig 1

2.3.2 Exclusion criteria

Studies without sound methodologies, and review and meta-analysis were not included in this analysis. Those articles which have no full information important for the analysis and case reports were excluded from the study. Duplication of results in studies and outcome variable measures with inconsistency were excluded from the final analysis. Studies, which incorporate other types of congenital anomalies were excluded (Fig 1).

2.4 Operational definition

Structural congenital anomalies: are structural changes, whether substantial or slight, that have a significant impact on an individual’s health or appearance and often demand for medical attention.

Resource-limited setting: were categorized as low-income nations by the World Bank, a global alliance of nations devoted to eradicating poverty, which determined that they had the weakest economy [27].

Unidentified drug use: using a drug that has not been approved for the client by the clinician and that might affect the mother’s or fetus natural physiological function.

Birth weight: Birth weight less than 2,500 grams was considered as low birth weight, whereas birth weight exceeding this was seen as normal [28].

Chewing chat: In this study “chewing chat” was marked with “yes” if a mother of a newborn with at least a weekly chat chewing experience.

Chemical exposure: A mother of the neonate who has jobs exposing to chemicals in a measurement of the amount and the frequency with which, a substance comes into contact.

Never using folic acid: A person whose most recent pregnancy was preceded by no folic acid use.

2.5 Quality assessment and data extraction

The basic quality of included research articles was evaluated using the Newcastle-Ottawa Scale (NOS). NOS were designed to assess the quality of observational research articles in meta-analyses. Data from this study were extracted by the two authors (YFG and YYL) using a standardized checklist for extracting data on an Excel sheet.

This meta-analysis uses the PRISMA flowchart to differentiate and select items of significance to the analysis. Initially, duplicate types of studies were not included using the Endnote version X8.1 referencing tool. Articles were excluded by adding highlights by going through their titles and abstracts before evaluating the entire text. Full-text studies or research results have been evaluated for other studies. Based on the aforementioned eligibility criteria; items have been assessed for eligibility.

Data were extracted using the standardized data extraction tool in considering the name of the first author, publication year, country of study, author’s affiliation, sample size, magnitude of antenatal exercise and their 95% confidence interval (Table 1). All literacies were independently verified by the two authors (YFG and YYL). Where disagreements have occurred, the articles have been reviewed by one of the authors (TMB) and used as final mediation and admissibility decision. To obtain the pooled possible risk factor of congenital anomalies random effect model was used with a p value less than 0.001.

Table 1. Descriptive summary of included articles to pool possible risk factors of congenital anomalies in low resource setting, 2022.

Authors Year Design Study area Sample size Number of cases inclusion criteria of cases
Abebe et al. [39] 2021 Case-control Southwestern Ethiopia 1,138 251 Live birth or fresh stillbirth
Bekalu et al. [36] 2019 Cross-sectional Jimma 754 31 Total births with CAs
Eshete et al. [38] 2020 Case-control Addis Ababa 116 3215 Total births with CAs
Feredegn et al. [33] 2018 Cross-sectional Addis Ababa 271 97 Live births
Gedamu et al. [31] 2021 Cross-sectional Bishoftu 2,218 23 Live births
Jemal et al. [37] 2021 Case-control Arsi 418 105 Total births externally visible defects
Mekonnen et al. [30] 2021 Cross-sectional Bahir Dar 11,177 69 Total births with CAs
Musa et al. [34] 2020 Cross-sectional Addis Ababa 116 71 Live births
Silesh et al. [35] 2021 Cross-sectional Jimma 3,346 199 Live births
Taye et al. [32] 2019 Cross-sectional Addis Ababa and Amhara 76,201 1518 Live births

2.6 Data synthesis and analysis

Both systematic review and meta-analysis were and the software used for the analysis was STATA version 14.0. Quantitative reviews were conducted to determine the overall pooled possible risk factors of structural congenital anomalies in low resource setting. The degree of heterogeneity between the included studies was evaluated by determining the p-values of I2-test statistics. I2 test statistics scores of 0, 25, 50, and 75% were taken as no, low, moderate, and high degrees of heterogeneity, respectively [29]. Due to the observed high heterogeneity across studies, we used a random effect model to assess pooled estimate. Publication bias was checked by funnel plot. A p-value of less than 0.05 was used as the cutoff point for statistical significance of publication bias.

2.7 Ethics approval and consent to participate

Ethical approval for this study was not applicable since this study was analyzed from secondary data without patient identification.

Results

3.1 Characterization of included studies

Ten articles were included in this systematic review and meta-analysis and it was summarized in Table 1. Seven articles of the included study had used cross-sectional study design [3036] while three articles were case control studies [3739] with a sample size ranging from 418 in Arsi [37] to 76,201 in Addis Ababa and Amhara region [32].

In relation to the geographical location in which the study was conducted, six articles were from central Ethiopia [3134, 37, 38], one study from Northern Ethiopia [30] and three studies from south western Ethiopia [35, 36, 39] (Table 1).

3.2 Publication bias

Bias among the included studies was checked by the funnel plot at a 5% significance level. The funnel plot was symmetry, and showed no statistical significance for the presence of publication bias for each variable. Egger test was done and verified that there was no small-study effects with P = 0.063 (Fig 2).

Fig 2. Funnel plot for studies on possible risk factors of congenital anomalies in resource limited setting, 2022.

Fig 2

3.3 Structural congenital anomalies

Only cross-sectional studies eligible for the analysis have reported prevalence of structural congenital anomalies. The overall pooled effect estimate of structural congenital anomalies was 5.50 with 95% confidence interval of 4.88 to 6.12 (Fig 3).

Fig 3. Forest plot for structural congenital anomalies in resource limited setting, 2022.

Fig 3

3.4 Possible risk factors of Congenital anomalies in low resource setting

In this systematic review and meta-analysis previous history of abortion, maternal illness, history of alcohol intake during pregnancy, unidentified drug use, birth weight, chewing chat, chemical exposure and taking folic acid tablets during pregnancy were statistically significant at one or more of the included primary studies. However, maternal illness, unidentified drug use, birth weight, chewing chat, chemical exposure and taking folic acid tablets during pregnancy were staying statistically significant in this meta-regression.

This review analyzed data from 95,755 women who have birth to estimate the pooled possible risk factors of congenital anomalies in low resource setting. A total of 10 (9 published and one unpublished) articles was included in this review (Table 1).

3.4.1 Maternal illness

Meta-analysis pooling of aggregate data using the random-effects and inverse-variance model with Der-Simonian-Laird estimate of tau2 was done for ‘maternal illness’ separately. Test of the pooled overall effect provides 4.93 with a 95%CI 1.02–8.85; which shows neonates of woman with previous illness were 4.93 times more likely to have structural congenital anomalies compared to women who have no history of illness (Table 2).

Table 2. Meta-regression result of pooled possible risk factors of congenital anomalies in resource limited setting, 2022.
Authors Effect [95% Conf. Interval] % Weight
Maternal illness
Jemal et al. [37] 6.10 2.39–15.57 35.23
Bekalu et al. [36] 4.30 1.65–11.37 64.77
Overall pooled 4.93 1.02–8.84 100.00
Unidentified drug use
Abebe et al. [39] 3.4 2.0–5.8 42.77
Feredegn et al. [33] 2.2 1.1–4.0 56.35
Bekalu et al. [36] 15.1 5.5–40.2 0.88
Overall pooled 2.83 1.19–4.46 100
Birth weight <2.5kg
Mekonnen et al. [30] 4.56 2.76–7.55 75.55
Gedamu et al. [31] 3.10 1.23–9.65 24.45
Overall pooled 4.20 2.12–6.28 100.00
Chat chewing
Bekalu et al. [36] 3.41 1.50–7.90 62.88
Jemal et al. [37] 4.76 1.57–14.47 15.48
Abebe et al. [39] 3.93 1.30–12.20 21.64
Overall pooled 3.73 1.20–6.30 100.00
Chemical exposure
Jemal et al. [37] 4.76 1.57–14.47 41.70
Abebe et al. [39] 3.93 1.26–12.17 58.30
Overall pooled 4.27 1.19–8.44 100.00
Never use folic acid
Jemal et al. [37] 0.57 0.41–0.73 25.00
Abebe et al. [39] 1.78 1.38–2.17 24.99
Bekalu et al. [36] 4.10 3.89–4.22 25.00
Gedamu et al. [31] 17.64 17.50–17.78 25.00
Overall pooled 6.01 2.87–14.89 100.00

3.4.2 Unidentified drug use

Meta-regression of ‘unidentified drug use’ with the data using the random-effects and inverse-variance model shows unidentified drug use during pregnancy had significantly associated with congenital anomalies in low resource setting. Women who had a history of unidentified drug use during pregnancy were 2.83 times more likely to have structural congenital anomalies compared to women who haven’t history of drug use during pregnancy (Table 2).

3.4.3 Birth weight

Birth weight was found to be statistically significant variable associated with structural congenital anomalies in resource limited settings. Neonates with birth weight less than 2.5kg were more likely to have structural congenital anomalies compared to neonates with birth weight greater than or equal to 2.5kg. The meta-regression of birth weight considering random-effects and inverse-variance model had 4.2 overall effects with a 95% confidence interval of 2.12 to 6.29 (Table 2).

3.4.4 Chat chewing

Pregnant women who have chat chewing experience were found to be significantly having structural congenital anomalies in the primary studies. The overall pooled effect women chewing chat were 3.73 times more likely to have structural congenital anomalies compared to women who never chew chat (Table 2).

3.4.5 Never use folic acid

Never using folic acid was a statistically significant variable in number of primary studies and in the meta-regression as well. Pregnant women who haven’t used iron folate were 6.01 times more likely to have neonates with structural congenital anomalies compared to who have used folic acid during and before pregnancy (Table 2).

3.4.6 Subgroup analysis to pool possible risk factors of structural congenital anomalies

The listed individual variables were repeated in the analysis of a study within subgroups of subjects defined by a subgrouping variable. Each variable was presented with I2 and P-value to see the heterogeneities between studies (Fig 4).

Fig 4. Forest plot of subgroup analysis by variables for pooled possible risk factors of congenital anomalies in resource limited setting, 2022.

Fig 4

Discussion

The overall pooled effect estimate of structural congenital anomalies in resource limited setting was 5.50 with 95% confidence interval of 4.88 to 6.12. On the Meta-regression maternal illness, unidentified drug use, birth weight, chewing chat chemical exposure and never using folic acid were found to be statistically significant variables which might be the possible risk factors of congenital anomalies in low resource setting.

This study had come up with maternal illness was one of the possible risk factors of congenital anomalies in resource limited settings. Consistently a study concluded that maternal exposure to illness, fever, and medication (particularly aspirin) may increase the risk of congenital anomalies [40]. Another study conducted on the association between congenital anomalies and gestational diabetes mellitus stated that there was an increased rate of congenital anomalies in offspring of women with diabetes [41]. A study reported that first trimester maternal influenza exposure was associated with an increased risk of any congenital anomaly [42]. This might be due to causative agent of such diseases could pass the placental barrier and cause structural anomalies. However, experimental studies need to be conducted to confirm the associations.

This study verified that the unidentified drug use was one of the possible risk factors of congenital anomalies in resource limited settings. Similarly, studies showed that first-trimester paroxetine, fluoxetine, sertraline and anti-thyroid drug therapy exposures were associated with a significant increase in the risk of major congenital anomalies [4348].

This might be due to those drugs need to be categorized as drugs demonstrated fetal abnormalities. However, positive evidence of fetal risk in human exists, but the benefit from use in pregnant women may be acceptable in spite of the risk. Such as a life threatening situation for which a safer agent cannot be used.

In this study birth weight was found to be significantly affected congenital anomalies in low resource setting. In the same manner studies reported that congenital anomaly increased the risk of in-hospital mortality and was associated with short-term neonatal morbidities in low birth weight infants [49, 50]. Another study states that the prevalence of neonates with low birth weight and congenital anomalies was very high [51]. This might be due to fetuses with structural anomalies may have difficulties in using nutrients provided by the placenta appropriately due to their deformation. Moreover fetuses with structural anomalies are more likely to have functional anomalies which might disrupt metabolism and growth in the uterus.

In this study, chewing chat was the possible risk factor of congenital anomalies in low resource setting. Similarly a study conducted in Yemen clarifies that women who had chewed chat were more likely to have a poor neonatal outcome [52]. This might show that chemical in chat could pass the placental barrier and cause the anomalies. In the other hand, consumption of chat affects the growth of the fetus by inhibiting blood flow from the uterus to the placenta, which in turn affects the normal growth of the fetus.

This study revealed that chemical exposure was the possible risk factor of congenital anomalies in low resource setting. Consistently a study investigated of the strong association between congenital anomalies and mothers’ exposure to air pollution by nitrogen dioxide during pregnancy by combining risk estimates for a variety of air pollutants [53]. Another study reported that evidence for an effect of ambient air pollutants on congenital anomaly risk [54]. This might show that chemicals in work or living environment pregnant women could cause structural congenital anomalies. This may suggest that specially work environment of pregnant women needs to be screened for potential chemicals able to cause anomalies.

This study showed that clients who had never taken folic acid tablet were more likely to develop congenital anomalies, or clients who had taken folic acid tablet were less likely to develop congenital anomalies compared to those who haven’t taken folic acid. Similarly a study states that maternal preconception folic acid supplementation was significantly associated with the risk of congenital anomalies [55]. A study shows a robust estimate of the positive association between maternal folate supplementation and a decreased risk of congenital anomalies [56]. This might be due to intake of folic acid prior to conception and during the early stages of pregnancy plays an important role in preventing structural congenital anomalies.

Strength and limitation

This systematic review and meta-analysis brings summative analysis of all primary studies conducted in resource limited settings. All variables available in each article were assessed for significance in the pooled effect. Pooled possible risk factors of structural congenital anomalies were obtained and Pooled significant variables were identified. But this systematic review might not be generalized to all countries with the resource limited settings. Because the available primary studies were conducted in some of the regions of low income countries.

Conclusion and recommendation

The overall pooled effect estimate of structural congenital anomalies in a resource limited settings was high compared to those countries with better resources. On the Meta-regression maternal illness, unidentified drug use, birth weight, chewing chat, chemical exposure and never using folic acid were found to be statistically significant variables which might be the possible risk factors of congenital anomalies in low resource setting.

Therefore Women with illnesses like diabetes mellitus should be advised to have preconception care and antenatal care contact by the health offices in all resource limited settings.

Prevention based on reproduction options includes teratogen information like chewing chat, providing drugs without checking their teratogenicity, chemical exposure and prenatal screening for fetal anomalies should be done by all hospitals delivering preconception and pregnancy services.

Supporting information

S1 Table. PRISMA checklist.

(DOCX)

S2 Table. NOS quality assessment.

(DOCX)

S1 File. MeSH terms.

(DOCX)

S1 Dataset

(RAR)

Acknowledgments

Authors of the primary research used on this systematic review and meta-analysis never need to be missed from acknowledgment.

Abbreviations

CA

Congenital Anomalies

CI

Confidence Interval

EI

Effect Estimate

NOS

Newcastle-Ottawa Scale

OR

Odds Ratio

PRISM

Preferred Reporting Items of Systematic Reviews and Meta-Analysis

WHO

World Health Organization

Data Availability

The supporting data for these findings is accessible and is included with the paper as a supplementary file.

Funding Statement

The author) received no specific funding for this work.

References

  • 1.WHO. World Health Organization. Birth Defects Surveillance Training. 2016.
  • 2.WHO. World Health Organization, Congenital anomalies. 2016.
  • 3.C. B. Birth defects: epidemiology, types, and patterns. UpToDate; 2017. Accessed July 2, 2018. 2018. https://www.uptodate.com/contents/birth-defects-epidemiology-types-and-patterns
  • 4.Boyle B A M.C.; Arriola L.; Barisic I. Estimating Global Burden of Disease due to congenital anomaly. 2018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Obu HA C J, Uleanya ND, Adimora GN, Obi IE. Congenital malformations among newborns admitted in the neonatal unit of a tertiary hospital in Enugu, South-East Nigeri: a retrospective study. 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Ajao AE A I. Prevalence, risk factors and outcome of congenital anomalies among neonatal admissions in Ogbomoso, Nigeria. 2019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Stallings EB, Isenburg JL, Short TD. Population-based birth defects data in the United States, 2012–2016. 2019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Lee KS, Choi YJ, Cho J. Environmental and Genetic Risk Factors of Congenital Anomalies: An Umbrella Review of Systematic Reviews and Meta-Analyses. 2021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.WHO. World Health Organization. Congenital Anomalies. World Health Organization; 2018. http://www.who.int/news-room/fact-sheets/detail/congenital-anomalies.
  • 10.UN. European monitoring of congenital anomalies 2020. https://op.europa.eu/en/publication-detail/-/publication/cc2ffa13-d854-11ea-adf7-01aa75ed71a1/language-en.
  • 11.Tsehay B S D.; Lake A.; Abebaw E. Determinants and seasonality of major structural birth defects among newborns delivered at primary and referral hospital of East and West Gojjam zones, Northwest Ethiopia. 2019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Mendes ICJ, R.S.A.; Pinheiro. Anomalias congênitas e suas principais causas evitáveis: Uma revisão. 2018.
  • 13.Boyle B, Addor M-C., Arriola L., Barisic I., Bianchi F. Estimating Global Burden of Disease due to congenital anomaly: an analysis of European data. 2018. Available from: doi: 10.1136/archdischild-2016-311845 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.França EB L S.; Rego M.A.S. Leading causes of child mortality in Brazil, in 1990 and 2015: Estimates from the Global Burden of Disease study. 2017. [DOI] [PubMed] [Google Scholar]
  • 15.UKRI. Sub-Saharan African Network for Congenital Anomalies: Surveillance, Prevention and Care 2022. https://gtr.ukri.org/projects?ref=MR%2FT039132%2F1#/tabOverview.
  • 16.WHO. Congenital anomalies 2022. https://www.who.int/teams/integrated-health-services/clinical-services-and-systems/surgical-care/congenital-anomalies.
  • 17.Geneti SA, Dimsu GG, Sori DA. Prevalence and patterns of birth defects among newborns in southwestern Ethiopia: a retrospective study. 2021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Mekonnen a, MollaTaye, Worku W. Congenital anomalies among newborn babies in Felege-Hiwot Comprehensive Specialized Referral Hospital, Bahir Dar, Ethiopia. 2021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Taye M, Afework M, Fantaye W. Magnitudeof Birth Defects in Central and Northwest Ethiopiafrom 2010–2014: A Descriptive Retrospective Study. 2016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.WHO. Congenital anomalies 2021. https://www.who.int/health-topics/congenital-anomalies#tab=tab_1.
  • 21.Edris Y, Abdurahman H, Desalew A, Weldegebreal F. Neural Tube Defects and Associated Factors among Neonates Admitted to the Neonatal Intensive Care Units in Hiwot Fana Specialized University Hospital, Harar, Ethiopia. Global Pediatric Health. 2020;7:2333794X20974218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Tsehay B, Shitie D, Lake A. Determinants and seasonality of major structural birth defects among newborns delivered at primary and referral hospital of East and West Gojjam zones, Northwest Ethiopia 2017–2018: case–control study. 2019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Sitkin NA O D.; Donkor P. Congenital anomalies in low- and middle-income countries: The unborn child of global surgery. 2015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Ajao AE A I.A. Prevalence, risk factors and outcome of congenital anomalies among neonatal admissions in OGBOMOSO, Nigeria. 2019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Lt Col Singh G SM K. Bad Obstetric History A Prospective Study. 2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med. 2021;18(3):e1003583. doi: 10.1371/journal.pmed.1003583 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Bank W. New World Bank country classifications by income level: 2022–2023. 2023.
  • 28.WHO/CDC/ICBDSR. Birth defects surveillance training: facilitator’s guide. Geneva: World Health Organization. WHO. 2015.
  • 29.Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine. 2002;21(11):1539–58. doi: 10.1002/sim.1186 [DOI] [PubMed] [Google Scholar]
  • 30.Mekonnen D, MollaTaye, Worku W. Congenital anomalies among newborn babies in Felege-Hiwot Comprehensive Specialized Referral Hospital, Bahir Dar, Ethiopia. Sci Rep. 2021;11(1):11027. doi: 10.1038/s41598-021-90387-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Gedamu S, Sendo EG, Daba W. Congenital Anomalies and Associated Factors among Newborns in Bishoftu General Hospital, Oromia, Ethiopia: A Retrospective Study. J Environ Public Health. 2021;2021:2426891. doi: 10.1155/2021/2426891 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Taye M, Afework M, Fantaye W, Diro E, Worku A. Congenital anomalies prevalence in Addis Ababa and the Amhara region, Ethiopia: a descriptive cross-sectional study. BMC Pediatr. 2019;19(1):234. doi: 10.1186/s12887-019-1596-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Talarge F, Seyoum G, Tamirat M. Congenital heart defects and associated factors in children with congenital anomalies. Ethiop Med J. 2018;56(4). [Google Scholar]
  • 34.Musa AH, Afework M, Bedru M, Tamirat S. Incidence of atrial septal defects in children attended the Cardiac Center of Ethiopia during January 2016 to December 2018. bioRxiv preprint 2020. [Google Scholar]
  • 35.Silesh M, Lemma T, Fenta B, Biyazin T. Prevalence and Trends of Congenital Anomalies Among Neonates at Jimma Medical Center, Jimma, Ethiopia: A Three-Year Retrospective Study. Pediatric Health Med Ther. 2021;12:61–7. doi: 10.2147/PHMT.S293285 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Getachew B. Prevalence of overt congenital anomalies, and associated factors among newborns delivered at jimma university medical center, southwest ethiopia. Jimma University repository. 2018.
  • 37.Jemal S, Fentahun E, Oumer M, Muche A. Predictors of congenital anomalies among newborns in Arsi zone public hospitals, Southeast Ethiopia: a case-control study. Ital J Pediatr. 2021;47(1):143. doi: 10.1186/s13052-021-01093-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Eshete M, Abate F, Abera B, Hailu A, Demissie Y, Mossey P, et al. Assessing the Practice of Birth Defect Registration at Addis Ababa Health Facilities. Ethiop J Health Sci. 2021;31(3):683–7. doi: 10.4314/ejhs.v31i3.26 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Abebe S, Gebru G, Amenu D, Mekonnen Z, Dube L. Risk factors associated with congenital anomalies among newborns in southwestern Ethiopia: A case-control study. PLoS One. 2021;16(1):e0245915. doi: 10.1371/journal.pone.0245915 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Abe Karon H MA, Moore Cynthia A. Maternal febrile illnesses, medication use, and the risk of congenital renal anomalies. birth defect. 2003;67(11). doi: 10.1002/bdra.10130 [DOI] [PubMed] [Google Scholar]
  • 41.Zhang TN, Huang XM, Zhao XY, Wang W, Wen R, Gao SY. Risks of specific congenital anomalies in offspring of women with diabetes: A systematic review and meta-analysis of population-based studies including over 80 million births. PLoS Med. 2022;19(2):e1003900. doi: 10.1371/journal.pmed.1003900 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Luteijn JM, Brown MJ, Dolk H. Influenza and congenital anomalies: a systematic review and meta-analysis. Hum Reprod. 2014;29(4):809–23. doi: 10.1093/humrep/det455 [DOI] [PubMed] [Google Scholar]
  • 43.Uguz F. Selective serotonin reuptake inhibitors and the risk of congenital anomalies: a systematic review of current meta-analyses. Expert Opinion on Drug Safety. 2020;19(12):1595–604. doi: 10.1080/14740338.2020.1832080 [DOI] [PubMed] [Google Scholar]
  • 44.Bar-Oz B, Einarson T, Einarson A, Boskovic R, O’Brien L, Malm H, et al. Paroxetine and congenital malformations: Meta-Analysis and consideration of potential confounding factors. Clinical Therapeutics. 2007;29(5):918–26. doi: 10.1016/j.clinthera.2007.05.003 [DOI] [PubMed] [Google Scholar]
  • 45.Agrawal M, Lewis S, Premawardhana L, Dayan CM, Taylor PN, Okosieme OE. Antithyroid drug therapy in pregnancy and risk of congenital anomalies: Systematic review and meta-analysis. Clin Endocrinol (Oxf). 2022;96(6):857–68. doi: 10.1111/cen.14646 [DOI] [PubMed] [Google Scholar]
  • 46.Shen ZQ, Gao SY, Li SX, Zhang TN, Liu CX, Lv HC, et al. Sertraline use in the first trimester and risk of congenital anomalies: a systemic review and meta-analysis of cohort studies. Br J Clin Pharmacol. 2017;83(4):909–22. doi: 10.1111/bcp.13161 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Li H, Zheng J, Luo J, Zeng R, Feng N, Zhu N, et al. Congenital anomalies in children exposed to antithyroid drugs in-utero: a meta-analysis of cohort studies. PLoS One. 2015;10(5):e0126610. doi: 10.1371/journal.pone.0126610 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Yakoob MY, Bateman BT, Ho E, Hernandez-Diaz S, Franklin JM, Goodman JE, et al. The risk of congenital malformations associated with exposure to beta-blockers early in pregnancy: a meta-analysis. Hypertension. 2013;62(2):375–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Chung SH, Kim CY, Lee BS. Congenital Anomalies in Very-Low-Birth-Weight Infants: A Nationwide Cohort Study. Neonatology. 2020;117(5):584–91. doi: 10.1159/000509117 [DOI] [PubMed] [Google Scholar]
  • 50.Venetis CA, Papadopoulos SP, Campo R, Gordts S, Tarlatzis BC, Grimbizis GF. Clinical implications of congenital uterine anomalies: a meta-analysis of comparative studies. Reprod Biomed Online. 2014;29(6):665–83. doi: 10.1016/j.rbmo.2014.09.006 [DOI] [PubMed] [Google Scholar]
  • 51.Mekonen HK, Nigatu B, Lamers WH. Birth weight by gestational age and congenital malformations in Northern Ethiopia. BMC Pregnancy Childbirth. 2015;15:76. doi: 10.1186/s12884-015-0507-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Abdel-Aleem AM, Abdulbari Assad M.M. Khat Chewing During Pregnancy: an Insight on an Ancient Problem. Impact of Chewing Khat on Maternal and Fetal Outcome among Yemeni Pregnant Women. Journal of Gynecology and Neonatal Biology. 2015;1(2):28. [Google Scholar]
  • 53.Chen EK, Zmirou-Navier D, Padilla C, Deguen S. Effects of air pollution on the risk of congenital anomalies: a systematic review and meta-analysis. Int J Environ Res Public Health. 2014;11(8):7642–68. doi: 10.3390/ijerph110807642 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Vrijheid M, Martinez D, Manzanares S, Dadvand P, Schembari A, Rankin J, et al. Ambient air pollution and risk of congenital anomalies: a systematic review and meta-analysis. Environ Health Perspect. 2011;119(5):598–606. doi: 10.1289/ehp.1002946 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Wondemagegn AT, Afework M. The association between folic acid supplementation and congenital heart defects: Systematic review and meta-analysis. SAGE Open Med. 2022;10:20503121221081069. doi: 10.1177/20503121221081069 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Feng Y, Wang S, Chen R, Tong X, Wu Z, Mo X. Maternal folic acid supplementation and the risk of congenital heart defects in offspring: a meta-analysis of epidemiological observational studies. Sci Rep. 2015;5:8506. doi: 10.1038/srep08506 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Abay Woday Tadesse

31 May 2023

PONE-D-23-05213Structural congenital anomalies in resource limited setting, 2023: A systematic review and meta-analysisPLOS ONE

Dear Dr. Yohannes Fikadu Geda,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jul 15 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Abay Woday Tadesse

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We noticed you have some minor occurrence of overlapping text with the following previous publication(s), which needs to be addressed:

- https://doi.org/10.1016/S0095-4543(21)00887-3

- https://doi.org/10.1016/j.heliyon.2022.e11657

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed.

3. Thank you for stating the following financial disclosure: 

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 

At this time, please address the following queries:

a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution. 

b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c) If any authors received a salary from any of your funders, please state which authors and which funders.

d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. 

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

5. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript. 

6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

Additional Editor Comments:

Title: Structural congenital anomalies in resource limited setting, 2023: A systematic review and meta-analysis

General: The authors tried to review the title which is an important public health problems. The authors should include the following comments, suggestions, and questions. In addition, the manuscript could be benefited from native English language editors to improve the language of the manuscript to improve it, otherwise it is suitable for publication with current shape.

Background:

Authors should clearly indicate why they conduct this review and meta-analysis?

Methods:

Please revise your "MeSH terms" in PubMed and attach your search strategy for each databases you have listed as an additional file (supplementary file).

The eligibility criteria is not clearly stated. Where is PICO?

Who did searching, data extraction and what type study quality check method was employed in your case?

Results:

Figure 1 describe those excluded by setting and outcomes in your ‘study characteristics’ part and indicate the difference clearly. Similarly, indicate studies which were removed due to quality if any.

Table 1 indicated all studies were performed in Ethiopia, so why you talking about resource limited setting? The title is misleading the readers.

How taking folic acid tablet during pregnancy OR =6.01 (95%CI 2.87-14.89) was positively associated with outcome in contrast to what already known?

you missed some important papers:

doi: 10.1177/2333794X20974218

Additional files required for:

searching techniques for all databases

quality assessment grading using Newcastle-Ottawa Scale

Discussion:

Generally, the discussion is very shallow and needs revision.

The first and second paragraph is not related to discussion. The author should have focused on the summary finding in the first paragraph.

Authors should link their finding to previous studies and provide the possible reason behind for the complement and disagreement of the findings.

What are the implications of your findings?

Recommendations should summarize in one or two sentences based on your conclusion.

Did your findings support preconception care and vaccination care that you recommended?

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors tried to review the title which is an important public health problems. The neural tube defect is common problems in low and middle income countries due to different factors. The underutilization of health services including preconception service in this regions makes things complicated. Having the overall understanding of the problem is very relevant. However, authors should incorporate or answer the following comments, suggestions, and questions and improve the language of the manuscript to improve it, otherwise it is suitable for publication with current shape.

Title: Structural congenital anomalies in resource limited setting, 2023: A systematic review and meta-analysis

Is resource limited setting is well known in World Bank economic classification of countries? I.e., high income countries, middle income countries, low income countries etc.

Abstract

Your background claim that there is a paucity of studies with a comprehensive review of structural anomalies; hence what is this gaps has to do with pooling the existing evidences?

Make your aim in line with your title.

Who did searching, data extraction and what type study quality check method was employed in your case?

How taking folic acid tablet during pregnancy OR =6.01 (95%CI 2.87-14.89) was positively associated with outcome in contrast to what already known?

The authors should indicate how outcomes variables and explanatory variables such as maternal illness, birth weight, chewing chat, chemical exposure, taking folic acid during pregnancy, unidentified drugs etc. were measured.

Did your study/review support preconception care and vaccination care that you recommended?

Background

Indicate the location of the evidences and its context, i.e., whether it is in the globe, LMICs, SSA etc. and also indicate type of evidence whether it is review, report, article etc.

“……, there is no study that serves as a standard for such settings.” So are you going to conduct primary study?

Authors failed to indicate why they are performing this systematic review and meta-analysis. Why large geographic coverage was considered despite huge heterogeneity that it could result in?

How authors pooling observational studies identified risk factors?

Authors should have indicated how stakeholders benefitted from systematic review and meta-analysis, whether researchers, policy or program designers, clinicians, etc.

Method

Information source did not indicate the MeSH terms correctly, for instance the MeSH term for congenital abnormalities is ‘Congenital Abnormalities’ not “Congenital Abnormalities/abnormalities".

The sample search of PubMed is not well organized. The key terms are not exhaustive.

The eligibility is not well explained point by points. For instance how you managed studies that reported proportion of outcome only, non-structural congenital anomalies, etc.

Where is PICO or other?

The description following preceding figure 1 is study characteristic that should have been incorporated to result section.

Where are study selection and data extraction subtitles?

“Egger test was done and verified that there was no small-study effects.” Don’t you think this is part of result?

Result

Figure 1 describe those excluded by setting and outcomes in your ‘study characteristics’ part and indicate the difference clearly. Similarly, indicate studies which were removed due to quality if any.

Table 1 indicated all studies were performed in Ethiopia, hence why you talking about resource limited setting? Why not you say simple ‘Ethiopia’. The title mislead readers.

The funnel plot indicate asymmetry, not symmetry; what is cutoff point for egger test to declare insignificance? Please indicate with proper citation in method section.

Discussion

The first and second paragraph is not related to discussion. The author should have focused on the summary finding in the first paragraph.

“Selection and characterization of included studies” what selection have to do in the result section?

“To obtain the pooled possible risk factor of congenital anomalies random effect model was used with a p value less than 0.001.” Don’t you think this should have included in the method section?

How facility-based studies reported prevalence of structural congenital anomalies?

“Possible risk factors of Congenital anomalies in low resource setting” how authors identified risk factors using cross-sectional studies?

Authors should link their finding to previous studies and provide the possible reason behind for the complement and disagreement of the findings. For instance how maternal illness related to tubal defect and what is the reason behind? How chat chewing related to tubal defect? Have you included studies from eastern part of the country where chat chewing is relatively high? What is the pathophysiology behind? Why https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672758/ not included? Which specific maternal illness is associated with tubal defects? How? Why?

What are the implications of your findings?

Recommendations are not usually listed as you did, instead summarize in one or two sentences based on your conclusion.

Additional files

Where is searching techniques for all databases?

Where is quality assessment grading using Newcastle-Ottawa Scale?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Kasiye Shiferaw (PhD)

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Oct 13;18(10):e0291875. doi: 10.1371/journal.pone.0291875.r002

Author response to Decision Letter 0


16 Jun 2023

Dear editors we appreciate you considering publishing our work in one of your prestigious journal. Editors' and reviewers' issues have been thoroughly addressed, and adjustments have been made as necessary.

Dear reviewer, we are excited to incorporate your insightful criticism to improve our article. As a result, we changed the manuscript; the changes are indicated in the revised version by track changes. Below are detailed responses to the reviewer concerns.

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response: Revised was made in accordance with PLOSONE formatting samples.

2. We noticed you have some minor occurrence of overlapping text with the following previous publication(s), which needs to be addressed:

- https://doi.org/10.1016/S0095-4543(21)00887-3

- https://doi.org/10.1016/j.heliyon.2022.e11657

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed.

Response: The manuscript was revised based on the advice provided and altered as necessary. YFG is the corresponding author of this document and the second study listed with doi above, and both studies' designs are meta-analyses. Even with considerable cutting and paraphrasing, this might result in some text overlap on the methods and materials section.

3. Thank you for stating the following financial disclosure:

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

At this time, please address the following queries:

a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c) If any authors received a salary from any of your funders, please state which authors and which funders.

d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Response: Amendments were made based on the recommendations.

4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Response: Justification was made on the revised manuscript.

5. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

Response: Corrected

6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Response: Captions for supporting files are included in the revised version of the manuscript

Reviewer #1: The authors tried to review the title which is an important public health problems. The neural tube defect is common problems in low and middle income countries due to different factors. The underutilization of health services including preconception service in this regions makes things complicated. Having the overall understanding of the problem is very relevant. However, authors should incorporate or answer the following comments, suggestions, and questions and improve the language of the manuscript to improve it, otherwise it is suitable for publication with current shape.

Title: Structural congenital anomalies in resource limited setting, 2023: A systematic review and meta-analysis

Is resource limited setting is well known in World Bank economic classification of countries? I.e., high income countries, middle income countries, low income countries etc.

Response: Your concern was considered significant, and the operational definition of a resource-limited setting was added to the methods and materials section in the amended paper.

Abstract

Your background claim that there is a paucity of studies with a comprehensive review of structural anomalies; hence what is this gaps has to do with pooling the existing evidences?

Make your aim in line with your title.

Response: The error has been fixed in the current version. It was meant to imply that there are no studies that include a comprehensive review.

Who did searching, data extraction and what type study quality check method was employed in your case?

Response: The initials of authors conducted searching and data extraction were described in quality assessment and data extraction subsection of the Methods and materials section. The basic quality of included research articles was evaluated using the Newcastle-Ottawa Scale and included as a supporting file in the current version.

How taking folic acid tablet during pregnancy OR =6.01 (95%CI 2.87-14.89) was positively associated with outcome in contrast to what already known?

Response: This study claims that never using folic acid was positively associated with outcome.

The authors should indicate how outcomes variables and explanatory variables such as maternal illness, birth weight, chewing chat, chemical exposure, taking folic acid during pregnancy, unidentified drugs etc. were measured.

Response: Those variables are described in operational definition subsection of methods and materials section.

Did your study/review support preconception care and vaccination care that you recommended?

Response: Vaccination was removed from the recommendation section. All statistically significant factors in this study that could result in congenital abnormalities could be avoided if the client received preconception care. That’s why preconception care included in the recommendation.

Background

Indicate the location of the evidences and its context, i.e., whether it is in the globe, LMICs, SSA etc. and also indicate type of evidence whether it is review, report, article etc.

Response: The background was changed to reflect this.

“……, there is no study that serves as a standard for such settings.” So are you going to conduct primary study?

Response: Last paragraph of the background was intensively revised.

Authors failed to indicate why they are performing this systematic review and meta-analysis. Why large geographic coverage was considered despite huge heterogeneity that it could result in?

Response: Even though congenital abnormalities could be significantly reduced with preconception care, providing preconception care has been hampered in all resources-limited settings which make them homogeneous.

How authors pooling observational studies identified risk factors?

Response: The term "possible risk factors" was chosen for this study because, despite the fact that the primary studies were observational studies, it more accurately characterizes the components listed here than the term "associated factors."

Authors should have indicated how stakeholders benefitted from systematic review and meta-analysis, whether researchers, policy or program designers, clinicians, etc.

Response: It’s indicated in the final paragraph of the background section.

Method

Information source did not indicate the MeSH terms correctly, for instance the MeSH term for congenital abnormalities is ‘Congenital Abnormalities’ not “Congenital Abnormalities/abnormalities".

The sample search of PubMed is not well organized. The key terms are not exhaustive.

The eligibility is not well explained point by points. For instance how you managed studies that reported proportion of outcome only, non-structural congenital anomalies, etc.

Response: Revised and provided as a supporting file.

Where is PICO or other?

Response: Included in table 1

Where are study selection and data extraction subtitles?

Response: It’s included in quality assessment and data extraction subsection

“Egger test was done and verified that there was no small-study effects.” Don’t you think this is part of result?

Response: Yes it’s, and corrected accordingly.

Result

Figure 1 describe those excluded by setting and outcomes in your ‘study characteristics’ part and indicate the difference clearly. Similarly, indicate studies which were removed due to quality if any.

Table 1 indicated all studies were performed in Ethiopia, hence why you talking about resource limited setting? Why not you say simple ‘Ethiopia’. The title mislead readers.

Response: Studies carried out in settings with limited resources were thoroughly reviewed. Unfortunately, no studies have been conducted in environments other than Ethiopia that meet the inclusion criteria. Until articles are available, those initial research carried out in Ethiopia were thought to nominate the poor resource situation of low-income countries. Additionally, it is believed to be employed as an evidence-based practice in low resource settings to intervene with congenital abnormalities.

Discussion

The first and second paragraph is not related to discussion. The author should have focused on the summary finding in the first paragraph.

Response: Corrected accordingly

“Selection and characterization of included studies” what selection have to do in the result section?

Response: Title of the subsection was corrected.

“Possible risk factors of Congenital anomalies in low resource setting” how authors identified risk factors using cross-sectional studies?

Response: The goal was to use "possible risk factors" rather than "risk factors," which might be used in the same way that we say "associated factors".

Authors should link their finding to previous studies and provide the possible reason behind for the complement and disagreement of the findings. For instance how maternal illness related to tubal defect and what is the reason behind? How chat chewing related to tubal defect? Have you included studies from eastern part of the country where chat chewing is relatively high? What is the pathophysiology behind? Why https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672758/ not included? Which specific maternal illness is associated with tubal defects? How? Why?

Response: We apologize for the error in omitting such a significant paper from the study. However, we have now cited it. Since the primary studies that were included stated "maternal illness during pregnancy" as a variable, without identifying the type of illness; because of this we simply generalized it and assumed that any illness should be monitored cautiously to avoid congenital abnormalities. We advocate experimental research because the primary papers pooled in this analysis were quantitative observational studies that were unable to address some of the concerns outlined above, particularly the "how" ones.

What are the implications of your findings?

Recommendations are not usually listed as you did, instead summarize in one or two sentences based on your conclusion.

Response: the recommendation part was revised.

Additional files

Where is searching techniques for all databases?

Where is quality assessment grading using Newcastle-Ottawa Scale?

Response: provided as a supporting files.

Thank you!

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Abay Woday Tadesse

7 Sep 2023

Structural congenital anomalies in resource limited setting, 2023: A systematic review and meta-analysis

PONE-D-23-05213R1

Dear Dr. Geda Yohannes,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Abay Woday Tadesse

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

The authors should improve the language of the manuscript, otherwise it is suitable for publication with current shape.

Reviewers' comments:

Acceptance letter

Abay Woday Tadesse

6 Oct 2023

PONE-D-23-05213R1

Structural congenital anomalies in resource limited setting, 2023: A systematic review and meta-analysis

Dear Dr. Geda:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Mr. Abay Woday Tadesse

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. PRISMA checklist.

    (DOCX)

    S2 Table. NOS quality assessment.

    (DOCX)

    S1 File. MeSH terms.

    (DOCX)

    S1 Dataset

    (RAR)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    The supporting data for these findings is accessible and is included with the paper as a supplementary file.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES